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The nuclear hormone receptors liver X receptor a (LXRa) and peroxisome proliferator-activated
receptor c (PPARc) play key roles in the development of fatty liver. To determine the link between
hepatic PPARc and LXRa signaling and the development of fatty liver, a LXRa-speciﬁc ligand,
T0901317, was administered to normal OB/OB and genetically obese (ob/ob) mice lacking hepatic
PPARc (PparcDH). In ob/ob-PparcDH and OB/OB-PparcDH mice, as well as ob/ob-PparcWT and
OB/OB-PparcWT mice, the liver weights and hepatic triglyceride levels were markedly increased in
response to T0901317 treatment. These results suggest that hepatic PPARc and LXRa signals
independently contribute to the development of fatty liver.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Liver X receptor (LXR) a and b are members of a family of
ligand-dependent nuclear receptors. LXRs heterodimerize with ret-
inoid X receptors (RXRs) and regulate the transcription of target
genes by binding to LXR-responsive elements in the 50 regions
upstream of target genes. LXRs play important roles in the regula-
tion of genes associated with lipid metabolism [1]. Genes that
encode proteins involved in sterol metabolism including ATP-bind-
ing cassette transporters ABCA1, ABCG1, ABCG5, and ABCG8, as well
as apolipoprotein E and CYP7a1 are LXR targets. Further, LXRa also
plays important roles in the regulation of hepatic fat accumulation.
Two transcription factors, sterol regulatory element-binding
protein-1c (SREBP-1c) and carbohydrate response element-binding
protein (ChREBP), play key roles in LXRa-mediated hepatic lipo-
genesis. SREBP-1c is a basic helix-loop-helix family transcription
factor and a direct target of the LXRa/RXRa heterodimer [1].
SREBP-1c controls the expression of nearly all genes integral tolipogenesis, including fatty acid synthase (Fas), acetyl-CoA carbox-
ylase (Acc), and stearoyl-CoA desaturase 1 (Scd1) [1]. ChREBP is also
an LXR target gene [2]. ChREBP is a glucose-sensitive transcription
factor that promotes the hepatic conversion of excess carbohy-
drates to lipids [3]. Studies using mice lacking ChREBP expression
revealed that ChREBP regulates Fas, Acc, Scd1, and SREBP-1c [4].
LXRa signaling mediated by SREBP-1c and ChREBP contributes to
the increase in hepatic triglyceride content by upregulating lipo-
genic genes. Moreover, administration of the LXR ligand
T0901317 to mice induces severe fatty liver [5]. Therefore, LXRa
signaling is associated with the development of pathogenic condi-
tions such as hepatic steatosis.
The leptin-deﬁcient obese genetic background (ob/ob) mouse, a
typical type 2 diabetes model with severe fatty liver, was previ-
ously generated with hepatocyte-speciﬁc disruption of the gene
encoding peroxisome proliferator-activated receptor c (PPARc,
designated ob/ob-PparcDH. The ob/ob-PparcDH) mice showed recov-
ery from the severe fatty liver disease that was found in their
PPARc-expressing ob/ob-PparcWT counterparts, suggesting that
hepatic PPARc promotes the development of fatty liver [6]. To
determine the mechanism of PPARc-dependent development of
fatty liver, the levels of mRNAs encoded by lipogenic genes in the
livers of ob/ob-PparcDH and ob/ob-PparcWT and non-obese counter-
parts OB/OB-PparcDH and OB/OB-PparcWT were compared [6]. The
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and glycerol-3-phosphate acyltransferase (Gpat) were lower in
ob/ob-PparcDH livers than in those of ob/ob-PparcWT mice, suggest-
ing that PPARc promotes the development of fatty liver in ob/ob
mice by upregulating the expression of lipogenic genes. Notably,
these genes are also typical LXRa-SREBP-1c or LXRa-ChREBP
targets. Thus, these ﬁndings point toward a possible link between
LXRa and PPARc signaling in ob/ob fatty liver. Further, PPARc in
macrophages was shown to regulate directly the expression of
LXRa [7,8]. However, whether PPARc regulates LXRa expression
in the liver is not known.
In the present study, the role of hepatic PPARc in LXRa-associated
fat accumulation was determined using ob/ob-PparcDH mice. Our
results demonstrated that hepatic PPARc and LXRa independently
regulate the expression of lipogenic genes and development of
fatty liver in ob/ob mice. These ﬁnding suggests the presence of
two major signaling pathways involving two nuclear receptors,
which results in the development of fatty liver.
2. Materials and Methods
2.1. Mice
Hepatocyte-speciﬁc PPARc knockout mice were generated in
ob/ob (ob/ob-PparcDH) and normal genetic backgrounds (OB/OB-
PparcDH) using a Pparc-ﬂoxed allele and Cre recombinase transgene
under control of the albumin promoter as described previously [6].
Mouse experiments were performed under the guidelines of the
center for experimental animals of the Fukuoka University.
2.2. Administration of LXR ligand
The LXR ligand, T0901317 (Sigma–Aldrich, Japan) was adminis-
tered to the T0901317 group as described previously [5]. The
control group was not administered T0901317. Diets containing
0.025% T0901317 were prepared by mixing the ligand with
powdered chow (CE-2, CLEA, Japan).
2.3. Measurement of lipids
Total triglyceride and cholesterol contents were measured as
described previously [9].
2.4. RNA extraction and quantitative PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, Carls-
bad, CA, USA). Quantitative polymerase chain reaction (qPCR) was
performed using cDNA that was synthesized from 1 lg of total RNA
by using the AfﬁnityScript QPCR cDNA Synthesis kit (Agilent
Technologies). Sequences of the primers used were as follows:
LXRa forward, 50-ATCGCCTTGCTGAAGACCTCTG-30 and reverse,Table 1
Body weight and blood parameters in mice treated by LXR ligand.
PparcWT
OB/OB ob/ob
Control T0901317 Control T09
Body weight (g) 22.9 ± 1.3 26.9 ± 0.8* 38.7 ± 1.6 40.9
Glucose (mg/dl) 182 ± 20 188 ± 7.0 476 ± 85 258
Serum TG (mg/dl) 14.7 ± 1.5 12.9 ± 0.7 25.4 ± 2.7 25.
Serum CHO (mg/dl) 184 ± 8.0 265 ± 8.0*** 277 ± 12 378
Each group is from 5 to 9 mice. TG, triglyceride; CHO, total cholesterol; PparcWT, wild-typ
* p < 0.05.
** p < 0.01.
*** p < 0.001 versus control without T0901317.50-GATGGGGTTGATGAACTCCACC-30; PPARc forward, 50-CATGGCC
ATTGAGTGCCGAGT-30 and reverse, 50-ACATCCCCACAGCAAGGCAC-
30; Scd1 forward, 50-CGTCTGGAGGAACATCATTCT-30 and reverse,
50-CAGAGCGCTGGTCATGTAGT-30; Fas forward, 50-GGAGGTGGTGATA
GCCGGTAT-30 and reverse, 50-TGGGTAATCCATAGAGCCCAG-30; SREBP-
1c forward, 50-GGAGCCATGGATTGCACATT-30 and reverse, 50-AGG
AAGGCTTCCAGAGAGGA-30; Gpat forward, 50-TTGGGACTTGCACGT
TCTG-30 and reverse, 50-TAGGTTTGAACCCACAGTCAAC-30; ChREBP
forward, 50-ATTTCCTGGCTCCCAAGC-30 and reverse, 50-GAAGCAG
TCCAGGTCTAGAAGC-30; 36B4 forward, 50-AAACTGCTGCCTCACAT
CCG-30 and reverse, 50-TGGTGCCTCTGGAGATTTTCG-30; Lpk forward,
50-CATTGTGCTGACAAAGACTGG-30 and reverse, 50-AGCCTGTCACCA
CAATCACC-30; adipocyte fatty acid-binding protein (Ap2) forward,
50- GATGCCTTTGTGGGAACCTG-30 and reverse, 50-GAATTCCACGCC
CAGTTTGA-30; class B scavenger receptor (CD36) forward, 50-GAT
GACGTGGCAAAGAACAG-30 and reverse, 50-TCCTCGGGGTCCTGAGT
TAT-30. QPCR reactions were performed using Brilliant III Ultra-Fast
SYBR Green QPCR Master Mix (Agilent Technologies) and the
Mx3005P Real-Time PCR System (Agilent Technologies). 36B4
mRNA was used as an internal control.
2.5. Statistical analysis
Experimental values are expressed as the mean ± standard error
(SE). Statistical analyses were performed using the Student’s t-test
for unpaired data. p < 0.05 was considered statistically signiﬁcant.
3. Results
The LXR ligand T0901317 was administered at a concentration
of 0.025% in the diet for 7 days. Serum lipid and glucose content of
the mice are summarized in Table 1. The ob/ob genetic background
causes severe obesity and symptoms of type 2 diabetes. Hypergly-
cemia in ob/ob mice was signiﬁcantly suppressed by treatment
with T0901317. Consistent with a previous study [10], serum cho-
lesterol levels were increased in OB/OB-PparcWT and ob/ob-PparcWT
mice. However, the T0901317-induced changes in serum glucose
and cholesterol were similar to those in wild-type PPARc (PparcWT)
and PparcDH mice in an OB/OB or ob/ob genetic background. These
results suggested that hepatic PPARc was not involved in mediat-
ing the effects of T0901317 on serum cholesterol and glucose
levels.
The ob/ob-PparcWT mice had severe fatty liver. However, the liv-
ers of ob/ob-PparcDH mice showed recovery from fatty liver disease
(Fig. 1A), as reported previously [6]. Livers of T0901317-treated
ob/ob mice were signiﬁcantly enlarged compared to those of
untreated mice and were yellow in color (Fig. 1A). Notably,
T0901317-induced development of fatty liver was also observed
in ob/ob-PparcDH mice lacking hepatic PPARc. Treatment with
T0901317 led to a signiﬁcant increase in the liver weight and hepa-
tic triglyceride (TG) content in all mice (Fig. 1B and C). ThePparcDH
OB/OB ob/ob
01317 Control T0901317 Control T0901317
± 1.9 21.9 ± 1.3 22.3 ± 0.9 41.6 ± 0.5 40.3 ± 1.0
± 42* 214 ± 1.3 194 ± 8.0 516 ± 82 247 ± 40*
9 ± 4.0 16.9 ± 1.0 22.7 ± 4.4 39.7 ± 5.5 47.1 ± 7.6
± 15*** 192 ± 7.0 301 ± 10*** 307 ± 15 494 ± 39**
e PPARcmice; PparcDH, hepatocyte-speciﬁc PPARc null mice. Values are mean ± SE.
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Fig. 1. Effect of LXR ligand on hepatic triglyceride content in PparcDH mice. (A) T0901317-treated ob/ob-PparcWT or ob/ob-PparcDH livers. (B) Liver weight and (C) hepatic
triglyceride (TG) in mice belonging to each genotype. The number of mice belonging to each genotype was as follows. Control group (untreated): OB/OB-PparcWT, n = 5;
ob/ob-PparcWT, n = 9; OB/OB-PparcDH, n = 9; and ob/ob-PparcDH, n = 6. T0901317-treated group: OB/OB-PparcWT, n = 6; ob/ob-PparcWT, n = 8; OB/OB-PparcDH, n = 8; and
ob/ob-PparcDH, n = 6. Values are the mean ± SE. ⁄p < 0.01, ⁄⁄p < 0.001 versus the untreated control.
Table 2
Effect of LXR ligand on genes involved in lipid metabolism in PPARc-deﬁcient mouse liver.
Gene PparcWT PparcDH
OB/OB ob/ob OB/OB ob/ob
Control T0901317 Control T0901317 Control T0901317 Control T0901317
PPARc 1.0 ± 0.03 0.96 ± 0.04 1.0 ± 0.04 0.98 ± 0.02 N.D. N.D. 1.0 ± 0.13 1.1 ± 0.04
LXRa 1.0 ± 0.04 0.67 ± 0.01** 1.0 ± 0.03 0.52 ± 0.01*** 1.0 ± 0.07 0.84 ± 0.02* 1.0 ± 0.05 0.54 ± 0.02**
ChREBP 1.0 ± 0.07 1.3 ± 0.05* 1.0 ± 0.03 1.0 ± 0.01 1.0 ± 0.02 1.6 ± 0.01*** 1.0 ± 0.06 0.95 ± 0.04
SREBP-1c 1.0 ± 0.02 2.0 ± 0.10* 1.0 ± 0.02 1.0 ± 0.03 1.0 ± 0.03 2.5 ± 0.21* 1.0 ± 0.03 1.6 ± 0.05*
Fas 1.0 ± 0.05 11 ± 0.21*** 1.0 ± 0.09 3.1 ± 0.14** 1.0 ± 0.16 10 ± 0.10*** 1.0 ± 0.07 5.3 ± 0.17***
Scd1 1.0 ± 0.02 8.2 ± 0.49*** 1.0 ± 0.06 2.7 ± 0.05*** 1.0 ± 0.02 8.4 ± 0.45*** 1.0 ± 0.04 3.8 ± 0.11***
Gpat 1.0 ± 0.05 3.6 ± 0.07*** 1.0 ± 0.03 2.4 ± 0.04*** 1.0 ± 0.03 4.0 ± 0.03*** 1.0 ± 0.10 4.3 ± 0.05***
Lpk 1.0 ± 0.04 0.66 ± 0.01** 1.0 ± 0.05 0.89 ± 0.04 1.0 ± 0.07 1.4 ± 0.05*** 1.0 ± 0.09 1.0 ± 0.03
Ap2 1.0 ± 0.01 1.7 ± 0.33* 1.0 ± 0.06 1.6 ± 0.04** 1.0 ± 0.02 1.7 ± 0.14** 1.0 ± 0.06 1.4 ± 0.04**
CD36 1.0 ± 0.08 5.9 ± 0.05*** 1.0 ± 0.04 0.9 ± 0.10 1.0 ± 0.03 6.1 ± 0.14*** 1.0 ± 0.00 1.2 ± 0.01***
Each group is from 3 mice. PparcWT, wild type PPARcmice; PparcDH, hepatocyte-speciﬁc PPARc null mice ChREBP, carbohydrate response element-binding protein; SREBP-1c,
sterol regulatory element-binding protein-1c; Fas, fatty acid synthase; Scd1, stearoyl-CoA desaturase 1; Lpk, liver-type pyruvate kinase; Gpat, glycerol-3-phosphate
acyltransferase; Ap2, adipocyte fatty acid-binding protein; CD36, class B scavenger receptor. N.D., not detected. Values are mean ± SE.
* p < 0.05.
** p < 0.01.
*** p < 0.001 versus control without T0901317.
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similar to those in OB/OB-PparcWT and OB/OB-PparcDH mice. The
relative fold-inductions of TG by T0901317, compared to the
control, were as follows: OB/OB-PparcWT, 1.8-fold; OB/OB-PparcDH,
1.7-fold; ob/ob-PparcWT, 2.4-fold, and ob/ob-PparcDH, 2.5-fold.
The fold-induction of LXRa by T0901317 treatment in all mouse
genotypes was lower than that in untreated mice (Table 2). Previ-
ous studies demonstrated that LXRa is a direct target of PPARc in
macrophages [7,8]. Therefore, the level of LXRa mRNA expressed
in the livers of untreated PparcWT mice was compared with that
expressed in PparcDH livers. Consistent with a previous study [6],
the relative ratio of LXRa mRNA in PparcWT versus PparcDH
mice was nearly unchanged and were as follows: OB/OB-PparcWT:
OB/OB-PparcDH = 1.0:0.9 and ob/ob-PparcWT: ob/ob-PparcDH = 1.0:0.8.These data suggest that hepatic LXRa is not upregulated by PPARc.
Although ChREBP and SREBP-1c are also LXRa targets, the fold-
inductions in OB/OB-PparcWT and OB/OB-PparcDH mice were
greater than those in ob/ob-PparcWT and ob/ob-PparcDH mice
(Table 2).
In a previous report, several LXRa-SREBP-1c target genes in
ob/ob-PparcDH mouse livers were shown to decrease [6]. To exam-
ine the potential role of hepatic PPARc on the T0901317-mediated
induction of lipogenic genes, the relative fold-induction of LXRa-
SREBP-1c target genes for each genotype in the control and
T0901317 groups were compared (Table 2). T0901317 treatment
induced expression of Fas, Scd1, and Gpat mRNAs, known
hepatic LXRa-SREBP-1c [2] and PPARc targets [6], in PparcWT and
PparcDH mice with an OB/OB or ob/ob genetic background. The
LXRα
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FAS
ACCα
SCD1
ACCβ
ACL
GPAT PPARγ
 development of fatty liver
LXRα
SREBP-1c
ChREBP
FAS
ACCα
SCD1
ACCβ
ACL
GPAT
?
Normal liver
Fatty liver
LXRα signal PPARγ signal
LXRα signal
Fig. 2. Schematic diagram illustrating the independent effects of PPARc and LXRa in hepatic lipogenesis. The LXRa-SREBP-1c and ChREBP signals upregulate downstream
lipogenic genes in normal and obesity model mouse livers [2,5]. The expression of PPARc in normal livers is low, but is upregulated in ob/ob fatty livers [13]. The hepatic
PPARc pathway is likely more active in fatty liver rather than in normal livers. Therefore, hepatic PPARc appears to contribute signiﬁcantly to the development of fatty liver
rather than LXRa. ACC, acetyl-CoA carboxylase; ACL, ATP citrate lyase; GPAT, glycerol-3-phosphate acyltransferase; FAS, fatty acid synthase; SCD1, stearoyl-CoA desaturase 1.
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nearly identical to those in ob/ob-PparcDH mice as well as those
with an OB/OB genetic background. Following treatment with
T0901317, the ChREBP target gene Lpk [4] was induced only in
the livers of OB/OB-PparcDH mice. Ap2 and CD36 genes are well-
known PPARc targets. The fold-induction of Ap2 by T0901317
treatment in all mouse genotypes was slightly greater (approxi-
mately 1.5-fold) than that in untreated mice. The CD36 gene was
markedly induced by T0901317 treatment in OB/OB genetic back-
ground mice, but was unchanged in the livers of ob/ob background
mice. These results clearly suggested that hepatic PPARc did not
contribute to the induction of lipogenic genes and the develop-
ment of fatty liver following LXRa activation.
4. Discussion
A previous study revealed that in the fatty livers of ob/ob mice,
hepatic PPARc upregulates several lipogenic genes that are LXRa
targets [6]. These results suggested possible crosstalk between
LXRa and PPARc signaling pathways in the fatty livers of ob/ob
mice. In the present study, using hepatocyte-speciﬁc PPARc knock-
out mice, PparcDH, hepatic PPARc and LXRawere found to regulate
independently the expression of the lipogenic genes SREBP-1c, Fas,
Scd1, and Gpat. These results suggest that PPARc does not function
upstream or downstream of LXRa. The expression of PPARc in the
livers of mice fed a normal low-fat chow diet is very low [11].
However, PPARc is expressed at markedly elevated levels in the
fatty livers of a number of diabetes and obesity mouse models,
including ob/ob mice [12,13]. Although the mechanism of induc-
tion of PPARc in fatty liver remains unclear, a recent study showed
transcriptional regulation of PPARc by activator protein 1 (AP-1) is
involved [14]. Therefore, although hepatic PPARc and LXRa inde-
pendently regulate lipogenic genes, PPARc likely contributes to
the generation of fatty liver (Fig. 2).
Previous studies have found that LXRa is a direct target for
PPARc in macrophages [7,8]. The expression of LXRamRNA in mac-
rophages was induced by ligands for PPARc, but not by PPARa or
PPARb agonists. LXRa promoter activity is enhanced by PPARc,
which binds to PPAR-responsive elements in the LXRa promoter.
However, in the present and a previous study, hepatic LXRa
expression was nearly similar in PparcWT and PparcDH mice [6].
Therefore, PPARc does not appear to regulate directly the expres-
sion of LXRa in the liver. Indeed, LXRa is highly expressed in nor-
mal livers that express low, nearly undetectable levels of PPARc.
Therefore, PPARc regulates LXRa in a cell- or tissue-type speciﬁc
manner.Although lipogenic genes, Ap2 and CD36 were induced in
OB/OB- and ob/ob-PparcDH mice by LXR ligand, the degree of induc-
tion depended on each gene. These genes appeared to be indepen-
dently regulated by hepatic PPARc and LXRa. Ap2 and CD36 genes
are well known PPARc targets; however, these genes were induced
by LXR ligand. Recently, both genes were also reported as LXR
targets [15,16]. Interestingly, the induction of CD36 by T0901317
was observed in mice with an OB/OB genetic background, but not
in those with an ob/ob background. The mechanism remains
unclear and warrants further study.
The serum TG of T0901317-treated or untreated ob/ob-PparcDH
mice was higher than that of ob/ob-PparcWT mice (Table 1). The
details of this mechanism remain to be deﬁned; however, the
higher TG level in ob/ob-PparcDH mice was also reported in our
previous study [6]. The results of that study demonstrated that
very-low-density lipoprotein and chylomicron in ob/ob-PparcDH
mice accumulate in the blood. Therefore, the elevated TG level in
ob/ob-PparcDH mice may be due to having impaired TG-rich
lipoprotein clearance.
In summary, the present study demonstrated that PPARc and
LXRa independently regulate the expression of lipogenic genes
and contribute to the development of fatty liver. Lipogenesis is
known to contribute to the development of non-alcoholic fatty
liver disease (NAFLD) [17]. Therefore, a complete understanding
of these mechanisms might lead to the development of promising
new therapeutics to control hepatic TG accumulation in NAFLD.
Acknowledgments
This work was supported by the Mochida Memorial Foundation
for Medical Research and a KAKENHI Grant (No. 25460348).References
[1] Baranowski, M. (2008) Biological role of liver X receptors. J. Physiol.
Pharmacol. 59 (Suppl. 7), 31–55.
[2] Cha, J.Y. and Repa, J.J. (2006) The liver X receptor (LXR) and hepatic
lipogenesis: the carbohydrate-response element-binding protein is a target
gene of LXR. J. Biol. Chem. 282, 743–751.
[3] Uyeda, K., Yamashita, H. and Kawaguchi, T. (2002) Carbohydrate responsive
element-binding protein (ChREBP): a key regulator of glucose metabolism and
fat storage. Biochem. Pharmacol. 63, 2075–2080.
[4] Ishii, S., Iizuka, K., Miller, B.C. and Uyeda, K. (2004) Carbohydrate response
element binding protein directly promotes lipogenic enzyme gene
transcription. Proc. Natl. Acad. Sci. USA 101, 15597–15602.
[5] Chisholm, J.W. (2003) The LXR ligand T0901317 induces severe lipogenesis in
the db/db diabetic mouse. J. Lipid Res. 44, 2039–2048.
[6] Matsusue, K., Haluzik, M., Lambert, G., Yim, S.-H., Gavrilova, O., Ward, J.M.,
Brewer, B., Reitman, M.L. and Gonzalez, F.J. (2003) Liver-speciﬁc disruption of
K. Matsusue et al. / FEBS Letters 588 (2014) 2277–2281 2281PPARgamma in leptin-deﬁcient mice improves fatty liver but aggravates
diabetic phenotypes. J. Clin. Invest. 111, 737–747.
[7] Akiyama, T.E., Sakai, S., Lambert, G., Nicol, C.J., Matsusue, K., Pimprale, S., Lee,
Y.-H., Ricote, M., Glass, C.K., Brewer, H.B. and Gonzalez, F.J. (2002)
Conditional disruption of the peroxisome proliferator-activated receptor
gamma gene in mice results in lowered expression of ABCA1, ABCG1, and
apoE in macrophages and reduced cholesterol efﬂux. Mol. Cell. Biol. 22, 2607–
2619.
[8] Chawla, A., Boisvert, W.A., Lee, C.-H., Lafﬁtte, B.A., Barak, Y., Joseph, S.B., Liao,
D., Nagy, L., Edwards, P.A., Curtiss, L.K., Evans, R.M. and Tontonoz, P. (2001) A
PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol
efﬂux and atherogenesis. Mol. Cell 7, 161–171.
[9] Matsusue, K., Kusakabe, T., Noguchi, T., Takiguchi, S., Suzuki, T., Yamano, S. and
Gonzalez, F.J. (2008) Hepatic steatosis in leptin-deﬁcient mice is promoted by
the PPARgamma target gene Fsp27. Cell Metab. 7, 302–311.
[10] Schultz, J.R. (2000) Role of LXRs in control of lipogenesis. Genes Dev. 14, 2831–
2838.
[11] Tontonoz, P., Hu, E., Graves, R.A., Budavari, A.I. and Spiegelman, B.M. (1994)
MPPAR gamma 2: tissue-speciﬁc regulator of an adipocyte enhancer. Genes
Dev. 8, 1224–1234.
[12] Bedoucha, M., Atzpodien, E. and Boelsterli, U.A. (2001) Diabetic KKAy mice
exhibit increased hepatic PPARgamma1 gene expression and develop hepaticsteatosis upon chronic treatment with antidiabetic thiazolidinediones. J.
Hepatol. 35, 17–23.
[13] Memon, R.A., Tecott, L.H., Nonogaki, K., Beigneux, A., Moser, A.H., Grunfeld, C.
and Feingold, K.R. (2000) Up-regulation of peroxisome proliferator-activated
receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid
expression in the liver in murine obesity: troglitazone induces expression of
PPAR-gamma-responsive adipose tissue-speciﬁc genes in the liver of obese
diabetic mice. Endocrinology 141, 4021–4031.
[14] Hasenfuss, S.C., Bakiri, L., Thomsen, M.K., Williams, E.G., Auwerx, J. and
Wagner, E.F. (2014) Regulation of steatohepatitis and PPARc signaling by
distinct AP-1 dimers. Cell Metab. 19, 84–95.
[15] Seo, J.B., Moon, H.M., Kim, W.S., Lee, Y.S., Jeong, H.W., Yoo, E.J., Ham, J., Kang,
H., Park, M.-G., Steffensen, K.R., Stulnig, T.M., Gustafsson, J.-A., Park, S.D. and
Kim, J.B. (2004) Activated liver X receptors stimulate adipocyte differentiation
through induction of peroxisome proliferator-activated receptor gamma
expression. Mol. Cell. Biol. 24, 3430–3444.
[16] Zhou, J., Febbraio, M., Wada, T., Zhai, Y., Kuruba, R., He, J., Lee, J.H., Khadem, S.,
Ren, S., Li, S., Silverstein, R.L. and Xie, W. (2008) Hepatic fatty acid transporter
Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis.
Gastroenterology 134, 556–567.
[17] Shinji Tamura, I.S. (2005) Contribution of adipose tissue and de novo
lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1139.
